3038Kobe Bussan Co., Ltd.

🇯🇵 Japonya Borsası
3147.00
JPY
Analysis Scores
Lothien Robustness Score?
75/100
Very Strong
Neden bu skor?
Damodaran ?
72/100
Dalio Risk ?
94/100
Piotroski ?
2/9
Weak
Previous period ROA data missing (C1 delta-ROA); Total assets data missing → ROA cannot be calculated (C2); Önceki yıl borç/varlık verisi yok → kaldıraç azalması kontrol edilemedi (C5); Current ratio data missing (C6); current assets data missing → turnover calculation unavailable (C9)
Graham ?
Veri Yetersiz
Özkaynaklar negatif veya sıfır — Graham formülü pozitif defter değeri gerektirir
Active Metric?
4/4
Confidence?
75%
Lothien Robustness Summary
68/100
Lothien Sağlamlık: Güçlü (68/100)
Genel tablo olumlu. Finansal yapı sağlam, bazı riskler mevcut. | Kısa Vade: Olumlu | Uzun Vade: Nötr | Pozitif: 4 | Negatif: 1 | Nötr: 0
Net Kâr Pozitif
Son çeyrekte ¥29.5B net kâr açıklandı. Şirket kârlı.
Çeyreklik Kâr Artışı
Net kâr bir önceki çeyreğe göre %+316.3 arttı (¥7.1B → ¥29.5B). Kısa vadede olumlu momentum.
Çok Düşük F/K
Trailing F/K: 5.9. Piyasa şirketi kârına göre düşük fiyatlıyor. Ucuz görünüyor ama sebebi araştırılmalı.
Lothien Sağlamlık Skoru: 75/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı güçlü görünüyor.
Sonraki Çeyrek: Düşüş Beklentisi
Tahminine göre kâr %-67.9 düşebilir. Sonraki bilançoya dikkat.

Data date 2026-11-13 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-13
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Orta
252 days
Annual Volatility ?
%33.8
VaR 95% ?
%3.55
daily max loss
VaR 99% ?
%5.00
daily max loss
CVaR 95% ?
%4.34
expected loss (tail)
Max Drawdown ?
%36.0
15.12.2025 → 19.06.2026
Skewness ?
0.50
Parametrik%3.55
Historik%3.30
Cornish-Fisher%3.17
Return Distribution
Valuation
Potential?
+0.4%
ROIC ?
42.5%
DCF Value ?
4,213.55
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/9
Son 2 çeyrek ardışık kâr
Fiyat TRAMA-99 üzerinde: %+10.7 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 2842.87 JPY
Fundamental & Technical Analysis
Profitability
No balance sheet data
Valuation
P/E Ratio 5.9x Sector: 17.8x
F/K 5.9x — sector median's (17.8x) %67 below. Attractive for value investing.
P/B Ratio 4.04x Sector: 1.79x
PD/DD 4.04x — sector median's %126 above. Expensive book value.
EV/EBITDA 11.9x Sector: 10.1x
EV/EBITDA 11.9x — sector median's (10.1x) %18 above. Expensive relative to EBITDA.
Indebtedness
Current Ratio 2.42x
Current ratio 2.42x — current assets are 2x short-term liabilities. Very healthy liquidity.
Net Debt / EBITDA 0.6x
Net Debt/EBITDA 0.6x — very low debt burden. Company can repay debt quickly.
Debt / Equity 0.17x
Low leverage — majority of assets financed by equity.
Interest Coverage 2100.7x
Interest coverage 2100.7x — very wide margin for paying interest expenses.
Growth
No balance sheet data
Score Explanations
Lothien Robustness
75/100
Very strong robustness score (75/100). Damodaran valuation, Dalio risk analysis and balance sheet quality criteria are largely met.
Very Strong
Potential
+0.4%
Plus %0.4 expected value (3152.82) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %75.
Components: PE target: 4264.14 | P/B target: 1469.94 | EV/EBITDA target: 2669.30 | DCF target: 4213.55
Damodaran Valuation
72/100
Strong Damodaran valuation (72/100). ROIC (%42.5) exceeds cost of capital, company creates value.
Strong
Dalio Risk Analysis
94/100
Low debt risk (94/100). Interest coverage ratio 2100.7x — strong. Debt/EBITDA 0.6x — in healthy range.
Leverage: 92/100 | Debt Service: 100/100 | Quality: 77/100
ROIC - Return on Capital
%42.5
ROIC (%42.5) cost of capital 34.8 bps above → company creates value.
WACC: %7.6
DCF Discounted Cash Flow
4,213.55
DCF modeli 4213.55 target value produced — compared to current price %34.1 undervalued.
Current price: 3141.00
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
2/9
Weak Piotroski (2/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Total assets data missing → ROA cannot be calculated (C2)
Weak
Graham Intrinsic Value
—
⚖️ Sector Comparison
P/E Ratio
5.9x vs 17.8x
Sector median's %67 below — cheap
P/B Ratio
4.04x vs 1.79x
Compared to sector %126 more expensive (by book value)
EV/EBITDA
11.9x vs 10.1x
Compared to sector %18 higher EV/EBITDA
ROIC vs WACC
%42.5 vs %7.6 WACC
ROIC 34.8 bps above cost of capital
TRAMA-99 Trend — Uptrend
Price (3147.00), TRAMA-99 line's %10.7 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 3147.00
TRAMA: 2842.87
Difference: %+10.7
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
3038 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.